• Tamara Pilishvili, Katherine E Fleming-Dutra, Jennifer L Farrar, Ryan Gierke, Nicholas M Mohr, David A Talan, Anusha Krishnadasan, Karisa K Harland, Howard A Smithline, Peter C Hou, Lilly C Lee, Stephen C Lim, Gregory J Moran, Elizabeth Krebs, Mark Steele, David G Beiser, Brett Faine, John P Haran, Utsav Nandi, Walter A Schrading, Brian Chinnock, Daniel J Henning, Frank LoVecchio, Joelle Nadle, Devra Barter, Monica Brackney, Amber Britton, Kaytlynn Marceaux-Galli, Sarah Lim, Erin C Phipps, Ghinwa Dumyati, Rebecca Pierce, Tiffanie M Markus, Deverick J Anderson, Amanda K Debes, Michael Lin, Jeanmarie Mayer, Hilary M Babcock, Nasia Safdar, Marc Fischer, Rosalyn Singleton, Nora Chea, Shelley S Magill, Jennifer Verani, Stephanie Schrag, and Vaccine Effectiveness Among Healthcare Personnel Study Team.
• MMWR Morb. Mortal. Wkly. Rep. 2021 May 21; 70 (20): 753-758.

AbstractThroughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting. A test-negative case-control study is underway to evaluate mRNA COVID-19 vaccine effectiveness (VE) against symptomatic illness among HCP at 33 U.S. sites across 25 U.S. states. Interim analyses indicated that the VE of a single dose (measured 14 days after the first dose through 6 days after the second dose) was 82% (95% confidence interval [CI] = 74%-87%), adjusted for age, race/ethnicity, and underlying medical conditions. The adjusted VE of 2 doses (measured ≥7 days after the second dose) was 94% (95% CI = 87%-97%). VE of partial (1-dose) and complete (2-dose) vaccination in this population is comparable to that reported from clinical trials and recent observational studies, supporting the effectiveness of mRNA COVID-19 vaccines against symptomatic disease in adults, with strong 2-dose protection.

23 keywords...

hide…